Bio
 

With a double degree in Medicine and Pharmacy, Harald Schmidt has a passion for network and systems medicine to re-define what we call "disease" from a descriptive symptom- and organ-based to a mechanism-based approach by using big data, innovative target validation, new mechanism-based diagnostics and rapid repurposing of registered drugs for new clinical applications by network pharmacology. He performs high risk/high potential gain research in areas of major medical need, such as the development and commercialization of a first-in-class neuro-protective therapy in stroke, a therapy against a common and yet untreatable form of heart failure, and a therapy for resistant hypertension. He chaired the COST action OpenMultiMed on network and systems medicine and coordinates the H2020 project REPO-TRIAL on in-silico network pharmacology. From 2012-2017 he was awarded an ERC AdG, thereafter an ERC PoC grant. Together with Jan Baumbach he is co-editor-in-chief of the 2018 founded journal Systems Medicine and has founded the International Network and Systems Medicine Association (insma.org). His multi-national (Germany, USA, Australia, Netherlands) research experience in Academia, Industry (Abbott) and Biotech (Vasopharm) has led to high impact publications (Hirsch 94) with high socio-economic impact such as drug and diagnostics patents, spin-offs and patient benefit.